Pasar al contenido principal

DISEÑO, SINTESIS Y EVALUACION FARMACOLOGICA DE NUEVAS PROPARGILAMINAS NEUROPROTECTORAS PARA EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER

SAF2009-07271

•
Nombre agencia financiadora Ministerio de Ciencia e Innovación
Acrónimo agencia financiadora MICINN
Programa Programa Nacional de Proyectos de Investigación Fundamental
Subprograma Subprograma de Proyectos de Investigación Fundamental no Orientada
Convocatoria Proyectos I+D
Año convocatoria 2009
Plan Estatal 2008-2011 Plan Nacional de Investigación Científica, Desarrollo e Innovación Tecnológica
Unidad de gestión Subdirección General de Proyectos de Investigación
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100004837

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Recent advances in the multitarget-directed ligands approach for the treatment of Alzheimer's disease

  • León, Rafael
  • García, Antonio G.
  • Marco-Contelles, José
With 27 million cases worldwide documented in 2006, Alzheimer's disease (AD) constitutes an overwhelming health, social, economic, and political problem to nations. Unless a new medicine capable to delay disease progression is found, the number of cases will reach 107 million in 2050. So far, the therapeutic paradigm one-compound-one-target has failed. This could be due to the multiple pathogenic mechanisms involved in AD including amyloid β (Aβ) aggregation to form plaques, Ï„ hyperphosphorylation to disrupt microtubule to form neurofibrillary tangles, calcium imbalance, enhanced oxidative stress, impaired mitochondrial function, apoptotic neuronal death, and deterioration of synaptic transmission, particularly at cholinergic neurons. Approximately 100 compounds are presently been investigated directed to single targets, namely inhibitors of β and γ secretase, vaccines or antibodies that clear Aβ, metal chelators to inhibit Aβ aggregation, blockers of glycogen synthase kinase 3β, enhancers of mitochondrial function, antioxidants, modulators of calcium-permeable channels such as voltage-dependent calcium channels, N-methyl-D-aspartate receptors for glutamate, or enhancers of cholinergic neurotransmission such as inhibitors of acetylcholinesterase or butyrylcholinesterase. In view of this complex pathogenic mechanisms, and the successful treatment of chronic diseases such as HIV or cancer, with multiple drugs having complementary mechanisms of action, the concern is growing that AD could better be treated with a single compound targeting two or more of the pathogenic mechanisms leading to neuronal death. This review summarizes the current therapeutic strategies based on the paradigm one-compound-various targets to treat AD. A treatment that delays disease onset and/or progression by 5 years could halve the number of people requiring institutionalization and/or dying from AD., Contract grant sponsor: Fundación CIEN; Contract grant number: PI 016/09; Contract grant sponsor: Agencia Laín Entralgo; Contract grant number: NDG07/9; Contract grant sponsor: MICINN; Contract grant numbers: SAF2006-08764-C02-01; SAF2009-07271; Contract grant sponsor: CSIC-GRICES; Contract grant number: 2007PT-13; Contract grant sponsors: ISCIII; MICINN; Contract grant number: RD06/0026/1002 Retic ‘‘RENEVAS’’; Contract grant sponsor: Comunidad de Madrid; Contract grant number: S/SAL-0275-2006, Peer reviewed, Peer Reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's disease, design, synthesis, biochemical evaluation, ADMET, molecular modeling, and QSAR analysis of novel donepezil-pyridyl hybrids

  • Bautista-Aguilera, Oscar M..
  • Esteban, Gerard|||0000-0002-9383-2150
  • Chioua, Mourad
  • Nikolic, Katarina
  • Agbaba, Danica
  • Moraleda, Ignacio
  • Iriepa, Isabel
  • Soriano, Elena
  • Samadi, Abdelouahid
  • Unzeta López, Mercedes|||0000-0002-7113-3383
  • Marco-Contelles, José
The design, synthesis, and biochemical evaluation of donepezil-pyridyl hybrids (DPHs) as multipotent cholinesterase (ChE) and monoamine oxidase (MAO) inhibitors for the potential treatment of Alzheimer's disease (AD) is reported. The 3D-quantitative structure-activity relationship study was used to define 3D-pharmacophores for inhibition of MAO A/B, acetylcholinesterase (AChE), and butyrylcholinesterase (BuChE) enzymes and to design DPHs as novel multi-target drug candidates with potential impact in the therapy of AD. DPH14 (Electrophorus electricus AChE [EeAChE]: half maximal inhibitory concentration [IC] =1.1±0.3 nM; equine butyrylcholinesterase [eqBuChE]: IC.